Auris Medical Holding Ltd represents values of innovation, excellence, and patient-centricity. With a corporate philosophy focused on developing novel therapeutics for inner ear disorders and hearing loss, the company aims to improve the lives of individuals worldwide. Through its extensive research and development efforts, Auris Medical Holding Ltd strives to bring innovative treatments to market, addressing unmet medical needs and providing hope for those suffering from hearing-related conditions. By placing patients at the center of its mission, the company contributes to enhancing the quality of life by restoring or preserving hearing capabilities. Auris Medical Holding Ltd's commitment to cutting-edge research and patient well-being drives its vision for a world with improved auditory health.

Auris Medical Holding Ltd is primarily present in several countries and regions. The company has a global presence with a focus on key markets such as the United States, Europe, and Asia. In the United States, Auris Medical Holding Ltd operates through its subsidiary, AM-Pharma, while also having a strong presence in European countries like Germany and Switzerland. The company's expansion into the Asian market includes partnerships and collaborations for drug development and commercialization. With a diversified geographical presence, Auris Medical Holding Ltd aims to cater to a wide range of investors and maximize growth opportunities across different regions.

Auris Medical Holding Ltd has achieved significant milestones in its journey. The company successfully conducted Phase 3 clinical trials for its flagship product AM-101, a potential treatment for tinnitus. This marked a major achievement, as positive results were observed in patients suffering from acute inner ear tinnitus. Auris Medical Holding Ltd also received an FDA Breakthrough Therapy designation for AM-111, another product targeting acute inner ear hearing loss. These milestones highlight the company's commitment to developing innovative solutions for hearing-related disorders. With its groundbreaking research and development efforts, Auris Medical Holding Ltd continues to make remarkable strides in the field.

Auris Medical Holding Ltd is a pharmaceutical company founded in 2003 and headquartered in Hamilton, Bermuda. The company focuses on developing novel therapies for the treatment of inner ear disorders and hearing loss. Auris Medical is dedicated to improving the lives of patients through innovative research and development in the field of otolaryngology (ENT). With a team of experienced professionals and strong collaborations, the company aims to bring safe and effective treatments to market. Auris Medical Holding Ltd is committed to advancing medical knowledge and technologies to address the unmet needs of individuals with hearing-related conditions.

The main competitors of Auris Medical Holding Ltd in the market are XYZ Corporation and ABC Inc.

Auris Medical Holding Ltd is primarily active in the healthcare industry.

The business model of Auris Medical Holding Ltd revolves around developing and commercializing therapeutic solutions for hearing loss and tinnitus. With a focus on the inner ear, Auris Medical aims to address unmet medical needs and provide innovative treatments for these conditions. By leveraging its expertise in the field of otology, the company is dedicated to advancing its portfolio of pharmaceutical products. Auris Medical's business strategy involves conducting clinical trials, obtaining regulatory approvals, and fostering strategic collaborations to bring its therapies to patients worldwide.

Pašreizējais KGV Auris Medical Holding nevar tikt aprēķināts.

KUV šobrīd Auris Medical Holding nevar aprēķināt.

AlleAktien kvalitātes vērtējums Auris Medical Holding ir 1/10.

Pašreiz nevar aprēķināt apgrozījumu Auris Medical Holding.

Pašlaik peļņa Auris Medical Holding nevar tikt aprēķināta.

Auris Medical Holding Ltd is a biopharmaceutical company focused on developing therapies for ear and brain diseases. The company's main divisions include research and development, marketing and sales of products, and collaboration with partners and research institutions. Auris Medical's research and development unit collaborates closely with leading scientists and clinical experts using advanced technologies and methods to develop effective therapies for ear and brain diseases. The company's key products include therapies for tinnitus and hearing loss, as well as diagnostic devices to determine the underlying causes of these conditions. Auris Medical aims to market and sell its products globally to meet the needs of patients. By collaborating with partners and research institutions, Auris Medical can develop effective therapies and explore innovative technologies. The company also works with governments and nonprofit organizations to advance research and development in the field of ear and brain diseases.

Auris Medical Holding izmaksā dividendes 0 CHF, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Auris Medical Holding vai uzņēmums nedod dividendes.

Auris Medical Holding ISIN ir BMG070252017.

Auris Medical Holding WKN ir A2PJN3.

Auris Medical Holding simbols ir EARS.

Pēdējo 12 mēnešu laikā Auris Medical Holding maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Auris Medical Holding plāno maksāt dividendes 0 CHF apmērā.

Auris Medical Holding pašreizējā dividendu rentabilitāte ir .

Auris Medical Holding maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Auris Medical Holding pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CHF. Tas atbilst dividendes ražībai 0 %.

Auris Medical Holding tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Auris Medical Holding apmērā 0 CHF, kas tika izmaksāta 1.12.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 1.12.2024..

Pēdējās dividendes izmaksa notika 1.12.2024..

Gadā 2023, Auris Medical Holding izmaksāja 0 CHF dividendes.

Auris Medical Holding dividendes tiek izmaksātas CHF.